Immune changes that cause and may reverse chronic migraine
Mechanisms of migraine chronification and reversal
This project tests whether boosting the body's regulatory T immune cells with low‑dose interleukin‑2 can reduce long‑term, frequent migraine attacks in people with chronic migraine.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11303356 on NIH RePORTER |
What this research studies
Researchers are studying how certain T cells (immune cells) around the nerves that carry head pain become unbalanced in people with chronic migraine. They compare patient observations with experiments in a mouse model where repeated nitroglycerin triggers persistent migraine‑like sensitivity. In mice they give low‑dose interleukin‑2 to expand regulatory T cells and check whether this reverses nerve sensitization and pain behaviors. The work aims to link immune cell changes to persistent migraine and test an immune‑based way to reverse it.
Who could benefit from this research
Good fit: People with chronic migraine (frequent, long‑standing migraine headaches) would be the most relevant group for potential future treatments.
Not a fit: People with other types of headache (for example, tension‑type or cluster headache), migraine from a clear structural cause, or those who cannot receive immune therapies may not benefit.
Why it matters
Potential benefit: If successful, this could point to new immune‑based treatments—such as low‑dose interleukin‑2—that reduce or reverse chronic migraine.
How similar studies have performed: Low‑dose interleukin‑2 has successfully expanded regulatory T cells in other autoimmune and inflammatory diseases, but applying it to chronic migraine is a novel approach.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Cao, Yuqing — Washington University
- Study coordinator: Cao, Yuqing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.